American College

ACMG Foundation for Genetic and Genomic Medicine Elects Four Highly Accomplished Medical Genetics Professionals to its Board of Directors

Retrieved on: 
Thursday, April 11, 2024
Education, Disorder, Rady Children's Hospital, Entrepreneurship, Doctor of Philosophy, Pathology, ACMG, Medical director, American Academy, Veterinarian, Myriad Genetics, FACMG, Drug, Genetic testing, Baylor College of Medicine, Distinguishing, International HapMap Project, New York University, Clinical Pediatrics, National academy, Hospital, Hispanic, Book, Health, American Medical Association, Research, Pediatrics (journal), Mental health, Master of Science, Genetic distance, Pediatrics, Women's health, School, Washington State University, Society, Cancer, Partnership, Genomics, American College, Policy, Genetic, Disability studies, Developmental Biology (journal), Friends, Patient, MED, MBA, Baylor University

The ACMG Foundation is a national nonprofit foundation dedicated to facilitating the integration of genetics and genomics into medical practice.

Key Points: 
  • The ACMG Foundation is a national nonprofit foundation dedicated to facilitating the integration of genetics and genomics into medical practice.
  • The board members are active participants, serving as advocates for the ACMG Foundation and for advancing its policies and programs.
  • ACMG Foundation President Nancy J. Mendelsohn, MD, FACMG said, "We are pleased to welcome these four new members to the ACMG Foundation Board of Directors.
  • "I am honored for the opportunity to serve the ACMG again through participation in the Foundation Board of Directors.

Sage Veterinary Imaging Opens New Treatment Center in Spring

Retrieved on: 
Thursday, April 11, 2024
Pain, Kidney disease, Blood, American College, ACVR, Liver disease, Pet, Skin, SVI, Glomus tumor, Heart, Echocardiography, Veterinary medicine, Brain, ACL, Stomach, Human, Limp, Pancreatitis, Radio, MRI, Biopsy, Diagnosis, Medical imaging

SPRING, Texas, April 11, 2024 /PRNewswire/ -- Pets in the Houston area now have access to human-quality imagery to get the treatment they deserve, thanks to the new Sage Veterinary Imaging (SVI). Working closing with local veterinarians, SVI offers the latest research-grade technology to obtain highly detailed images that enable accurate diagnosis and effective treatment plans for area pets. The new clinic is located at 8101 Cypresswood, Spring.

Key Points: 
  • SPRING, Texas, April 11, 2024 /PRNewswire/ -- Pets in the Houston area now have access to human-quality imagery to get the treatment they deserve, thanks to the new Sage Veterinary Imaging (SVI).
  • "Our mission is to help find answers fast using our human-quality imaging, and work with local veterinarians to deliver the treatment your pet needs."
  • Sage Veterinary Imaging is accredited by the American College of Veterinary Radiology (ACVR) as a teaching hospital, and the Spring clinic includes:
    3T magnetic resonance imaging (MRI).
  • The Spring imaging center is the third location for SVI; other imaging centers are located in Sandy, Utah, and Round Rock, Texas.

ACE Welcomes Julio C. Morales Jr. as New Chief Information Officer

Retrieved on: 
Wednesday, April 10, 2024
Education, ACE, Student, American College, Nova Southeastern University, Strategic planning, Management

INDIANAPOLIS, April 10, 2024 /PRNewswire/ -- American College of Education® (ACE) is thrilled to announce the appointment of Julio C. Morales Jr. as its new chief information officer. With a proven track record of building and leading high-impact organizations' successful technology strategies, Morales is poised to make significant contributions to ACE's continued success.

Key Points: 
  • INDIANAPOLIS, April 10, 2024 /PRNewswire/ -- American College of Education® ( ACE ) is thrilled to announce the appointment of Julio C. Morales Jr. as its new chief information officer.
  • With a proven track record of building and leading high-impact organizations' successful technology strategies, Morales is poised to make significant contributions to ACE's continued success.
  • "Julio brings incredible insight and expertise to the table, and we're extremely excited to have him on board," ACE President & Chief Executive Officer Geordie Hyland said.
  • Morales' versatile experience and leadership in a broad array of industry settings position him well to enhance ACE's technological landscape.

Lynn Bruder Acquires Nucleus Healthcare, Establishes Woman-Owned Healthcare Recruiting and Staffing Powerhouse

Retrieved on: 
Wednesday, April 10, 2024
Nursing, Government, American College, Patient, Bruder, Organization, Nucleus

PHILADELPHIA, April 10, 2024 /PRNewswire/ -- Nucleus Healthcare (Nucleus), a premier staffing and recruitment agency based in Philadelphia has become a woman-owned business.

Key Points: 
  • PHILADELPHIA, April 10, 2024 /PRNewswire/ -- Nucleus Healthcare (Nucleus), a premier staffing and recruitment agency based in Philadelphia has become a woman-owned business.
  • Current CEO, Lynn Bruder, acquired Nucleus through NuForce, LLC, dba Nucleus Healthcare.
  • Nucleus Healthcare, a staffing and recruitment agency based in PA has been acquired by the current CEO, Lynn Bruder.
  • "I am thrilled and honored to transform Nucleus Healthcare into one of the nation's most sought-after recruiting and staffing companies.

EQS-News: Abivax reports 2023 financial results and operational update

Retrieved on: 
Wednesday, April 10, 2024
Q&A, Nomination, New Drug Application, Patient, Shanda, MRO, G&A, IND, EQT, Marketing, Research, EST, McKinsey & Company, Carcinoma, Schering-Plough, Partnership, Webcast, SVP, IBD, Inflammatory Bowel Diseases, American College, Safety, Phase 10, Compensated emancipation, BB Biotech, URD, IPO, F2G, Sofinnova, FDA, AbbVie, EUR, Abstract, Takeda, Pharmaceutical industry

Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.

Key Points: 
  • Total number of employees at the end of December 2023 was 61 and significantly increased compared to 2022, due to the implementation of the U.S. and European operational infrastructure.
  • Cash position (including other financial assets of EUR 9.0M) at the end of 2023 was EUR 261.0M, compared to EUR 27.0M at the end of 2022.
  • A webcast will be organized on Monday, April 8, 2024, at 2:30 p.m. CEST (8:30 a.m. EST) following the announcement of the 2023 yearly results.
  • The Abivax management will give an overview of the Company’s 2023 highlights and projects going forward, followed by a live Q&A session.

Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Retrieved on: 
Tuesday, April 2, 2024
Hypertrophy, Heart, CRDL, Patient, Mayo Clinic, PPAR, Agent handling, Cleveland Clinic, Fibrosis, European, Therapy, Myocarditis, Analysis, American Heart Association, Human, Massachusetts General Hospital, Pericarditis, MMT, Heart failure, American College, Safety, ODD, Cardiology, Clinical professor, Disease, Pericardium, Research, World Heart Federation, Management, University, Death, Pericardial effusion, Maverick, Reactive oxygen species, TSX, Priority review, FDA, Conversation, Financial statement, Inflammation, Fast Track, Calcium, Wound healing, API, Pharmaceutical industry

"Cardiol Therapeutics made important progress in 2023 and early 2024 as we pursued our primary objective of providing new therapeutic options to patients with poorly served heart diseases," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics.

Key Points: 
  • "Cardiol Therapeutics made important progress in 2023 and early 2024 as we pursued our primary objective of providing new therapeutic options to patients with poorly served heart diseases," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics.
  • In January 2023, Cardiol announced the first patient had been enrolled in the Company's Phase II open-label pilot study ("MAvERIC-Pilot") investigating the tolerance, safety, and efficacy of CardiolRx™ in patients with recurrent pericarditis.
  • In November 2023, Cardiol announced that it had exceeded 50% of the patient enrollment target for the MAvERIC-Pilot study.
  • In January 2024, Cardiol announced that ARCHER had exceeded 50% patient enrollment and was progressing ahead of the original study timeline.

iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting

Retrieved on: 
Monday, April 8, 2024
Prevalence, Cardiovascular disease, Sudden death, Radiology, Blood, Risk, Physician, ICAD, Patient, Ageing, Stroke, Research, Breast, Angiography, Death, Woman, American College, Breast cancer, Literature, Prognosis, Moyamoya disease, ACC, Medical imaging

The 15-site prospective study included 2D screening mammograms from women ages 20 to 100, with a median age of 56.

Key Points: 
  • The 15-site prospective study included 2D screening mammograms from women ages 20 to 100, with a median age of 56.
  • “The ProFound BAC AI algorithm may provide a critical surrogate biomarker for women at risk of heart disease or stroke,” said Dana Brown, president and CEO of iCAD.
  • The study also suggests the ProFound Heart Health AI algorithm can standardize BAC detection, potentially improving efficiency and reducing variability among observers.
  • Early cardiovascular disease detection is key, as among asymptomatic women, the first manifestation of underlying coronary heart disease is often acute myocardial infarction (MI) or sudden death.

Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World’ Study

Retrieved on: 
Monday, April 8, 2024
Observational study, Cardiovascular disease, University Medical Center, Patient, Angina, Șaeș, CCS, American College, University Medical Center Utrecht, DRS, Royal Brompton Hospital, MACE, Pharmaceutical industry

These findings confirm the positive, ‘real-world’ outcomes of Shockwave Reducer, a novel technology for the treatment of refractory angina.

Key Points: 
  • These findings confirm the positive, ‘real-world’ outcomes of Shockwave Reducer, a novel technology for the treatment of refractory angina.
  • Results were presented earlier today at the 73rd Annual Scientific Sessions of the American College of Cardiology in Atlanta, GA.
    REDUCER-I is a post-market, multi-center, observational study designed to collect long-term outcomes on Shockwave Reducer in a large, ‘real-world’ population of 400 patients.
  • “Results from the REDUCER-I study continue to demonstrate the safety and effectiveness of Shockwave Coronary Sinus Reducer as a novel therapy for refractory angina,” said Dr. Verheye.
  • Results from COSIRA-II are intended to support the regulatory filing for US FDA approval of Shockwave Reducer.

Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24

Retrieved on: 
Monday, April 8, 2024
Blood pressure, Exercise, MRCP, Patient, Heart rate, Heart, Journal, Aes, Medical Center, Quality of life, Efficacy, Heart failure, American College, HCM, Clinical trial, CPET, ACC, Pharmaceutical industry

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to improve patient symptoms and functional capacity by enhancing cellular energetics, today announced that results from the Phase 2 IMPROVE-HCM clinical trial, evaluating ninerafaxstat in patients with symptomatic nHCM, were presented in a late-breaking clinical trial session at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.24) and published in the Journal of the American College of Cardiology (JACC).

Key Points: 
  • “We are pleased with the IMPROVE-HCM clinical trial results presented today at ACC and simultaneously published in JACC, confirming the importance of these results for patients living with nHCM,” said Anne Prener, M.D., Ph.D., president and chief executive officer of Imbria Pharmaceuticals.
  • “Based on these positive results, we plan to initiate the Phase 3 FORTITUDE-HCM clinical trial in patients with symptomatic nHCM later this year.
  • Most treatment emergent adverse events (AEs) were self-limiting and mild to moderate in severity occurring in 24 ninerafaxstat treated patients (70.6%) vs. 20 patients on placebo (60.6%).
  • improved) from 31.2 to 30.9 in the ninerafaxstat treated group and worsened from 32.7 to 34.3 in the placebo group.

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

Retrieved on: 
Monday, April 8, 2024
FACC, American College, Atrial flutter, Patient, Journal, History, Doctor of Philosophy, MD, Ventricular fibrillation, ACC, Pharmaceutical industry

“The promising results of this real-world design study demonstrated patients’ ability to self-manage multiple episodes of PSVT with etripamil,” said David Bharucha, MD, PhD, FACC, Chief Medical Officer of Milestone Pharmaceuticals.

Key Points: 
  • “The promising results of this real-world design study demonstrated patients’ ability to self-manage multiple episodes of PSVT with etripamil,” said David Bharucha, MD, PhD, FACC, Chief Medical Officer of Milestone Pharmaceuticals.
  • CARDAMYST™, the conditionally approved brand name for etripamil nasal spray, if approved, will be the first rapid, reliable, and at-the-ready option in the acute treatment of PSVT.
  • NODE-303 (ClinicalTrials.gov ID NCT04072835 ) evaluated self-administered etripamil (70 mg, nasal spray) in an outpatient setting for up to multiple episodes of PSVT, without prior test dosing.
  • Both the presentation and publication will be available on the Milestone Pharmaceuticals corporate website at the conclusion of the ACC presentation.